Particulars Particulars

Venus Remedies Limited Super Specialty segments of Anti-infectives and Anti-Cancer formulations Is into critical care segment of Oncology, Cardiology, Neurology Amongst 1Venus Remedies is actively engaged in the specialty formulations business in Cephalosporins, FDC, Carbapenems (Injectables), all leading segments of Anti-Infectives segment of pharmaceuticals industry, along with the Oncology and specialty range of products in Hormones and Cardiology products in Prefilled Syringes & Infusions segment. Amongst 100 leading fixed dosage injectable manufacturer. 75 patents received from authorities THIS IS TO BE MENTIONED SEPARATELY UNDER head patents VRL is headquartered in Panchkula and has three manufacturing units at Panchkula and Baddi in India and Werne in Germany. Its research and development centre is located in Baddi.

Formatted Table

Ind Swift Labs is involved in Development of APIs, Finished Dosage forms, Non-Infringing Process & World Class facilities for Contract Manufacturing

Formatted: Font: 8 pt

Formatted: Font: 8 pt, English (India)

Segment

Manufacturin g Facility

The company has multi locational manufacturing sites for producing APIs. The WHO-GMP approved manufacturing facility at Punjab with 17 manufacturing blocks comprises Pilot Plant, dedicated blocks and multi-purpose blocks designed to comply with stringent USFDA and other regulatory standards. An API facility in the state of Jammu & Kashmir complying with cGMP requirements. The company possesses a cumulative reactor capacity of 370 m3, one of the largest in North India. Complex reaction capabilities and stringent controls provide an ideal base for innovative and quality products. Formatted: No bullets or numbering Formatted: Bulleted + Level: 1 + Aligned at: 0" + Indent at: 0.25" Formatted: Font: (Default) Arial, 8 pt, Font color: Black, English (India), Pattern: Clear Formatted: Bulleted + Level: 1 + Aligned at: 0" + Indent at: 0.25"

Portfolio of over 75 products. The unit at (Panchkula) to manufacture complex and intravenous products in the Antibiotics, Total Parenteral Nutrition (TPN), Neuro and other super specialty therapeutic segments. Its key products include Mebatic, Calridol, Moximicin, Neurotol and Glutapep, among others. The unit at (Baddi) manufactures high-end novel formulations across eight units dedicated to oncology liquid injections, oncology lyophilised, lyophilised injections, pre-filled syringes, cephalosporins, carbapenems, cardiology injections and liquid vials The unit manufactures key products like Sulbactomax, Vancoplus, Potentox, Tobracef, Supime,

Portfolio

Formatted: Bulleted + Level: 1 + Aligned at: 0.5" + Indent at: 0.75"

Zydotum, Pirotum, Ronem, Lastinem, Fejet, Actimycin, Megaparin, Taxedol, Paclitol, Oxol, Citabol and Carplat, among others., Comprehensive Range of Oncology Products kindly elaborate here the kind of products in brief

Accreditation

External Rating

European GMP, WHO-GMP, Latin American GMP (INVIMA), Ukrainian GMP, Zimbabwe GMP, Uganda GMP, Sudan GMP, Syrian GMP, Columbian GMP, Kenya GMP, Yemen GMP, Ethiopia GMP,GMP, GMP Botswana, GMP GCC, Saudi Arabian GMP and Iranian GMP, ISO 9001, ISO 14001 & OHSAS 18001 certified. BBB (-) Outlook) Outlook Stable (ICRA Rating) 2012.

Rank

Stock Price

Key Accolades

VRL is ranked 107th in Asia (Source: Bio Spectrum Asia) & among the top 500 Largest pharmaceuticals Companies in world. (Source: Plimsoll Worldwide Business Intelligence Report). Companys Share closed on Monday ,Monday, April2nd ,April2nd, 2012 at Rs. 167.35 with 52-Weeks High/Low of Rs 168/275.95. Awarded Best Innovation Award, 2011 in Gold Category by the India Innovation Programme, organised by Lockheed Martin (USA), FICCI and DST (India) for its wound healing products. Venus's ACHNIL receives Bio Spectrum Product of the Year 2012 award for its novel research product (Achnil) Pain Killer. Awarded Best Innovation Award, 2011 in Gold Category by the India Innovation Programme, organised by Lockheed Martin (USA), FICCI and DST (India) for its wound healing products. Mention here about recent award Received the BIZZ- Business Excellence Award 2011 from the US Received Quality Award 2011 in the gold category from BID at an international convention in Geneva, Switzerland. India Manufacturing Excel Award 2011. Awarded Best Innovation Award, 2010 in Gold Category by the India Innovation Programme, organised by Lockheed Martin (USA), FICCI and DST (India) for its wound healing products. Best SME Award 2008: Government of India Emerging SME 2007: Awarded By Dr. Manmohan Singh, Prime Minister of India.

Formatted Table

Safety &Welfare Awards: 2006 & 2007

R& D centre built up Area of 100,000 sq. ft. Having 9 Research Laboratories (kindly mention which laboratories we have) Research team comprises of 60 scientists and support staff, of which 60% are PhDs and Post Doctorates Approved by DSIR R& D Pipeline of Products Products SULBACTOMAX Indication First Line Therapy For ESBL Resistance Infection Empiric Therapy For Pneumonia & Nosocomial Infections Antibiotic Chemotherapy For Meningitis & Mrsa Infections Antibiotic Chemotherapy For LCU, R Ti Burn Paptients Novel NSAID Pain Killer Injection Nano Technology Based AntiAcne ,Micro Emulsion Solid Tumor Detection In Early Stages Status Marketed

Research Centre spread over the area of 35000 sq.ft. is engaged in developing process technology for APIs in different therapeutic categories. R&D projects include Crams for API Development Medicinal Chemistry development for various discovery projects Custom synthesis of various novel intermediates & specialty chemicals.

Formatted: Line spacing: single Formatted: Line spacing: single

POTENTOX

Marketed

Formatted: Line spacing: single

VANCOPLUS

Marketed

Formatted: Line spacing: single

TOBRACEF

Marketed

Formatted: Line spacing: single

R& DResearch & Development

ACHNIL

Marketed

Formatted: Line spacing: single Formatted Table

ACNANO

Phase3 Clinical Trial Completed

Formatted: Line spacing: single

TUMATREK

Phase2 Clinical Trial Completed

Formatted: Line spacing: single

VRP007

VRP008

VRP0010

Product For Breast& Ovarian Cancer FDC For Lmmuno Compromised Patients Immune Booster

Pre Clinical Trial Completed Pre Clinical Trial Completed Pre Clinical Trial Completed Pre Clinical Trial Completed Pre Clinical Trial Completed Pre Clinical Trial Completed Pre Clinical Trial

Formatted: Line spacing: single Formatted: Line spacing: single

Formatted: Line spacing: single Formatted: Line spacing: single Formatted: Line spacing: single Formatted: Line spacing: single Formatted: Line spacing: single

VRP0011

Oral Cancer Formulation Anti-Viral Formulation Detoxlfying Formulation Neuro Product

VRP0012

VRP0013

VRP1009

VRP1010

Anti-Obesity Formulation

Completed Pre Clinical Trial Completed

Formatted: Line spacing: single Formatted: Font: Bold

Status of Patents Received with Market Opportunity No of Patents Received 42

Formatted: No bullets or numbering

Product

Patent from Nation South Africa, India European Union (No37) Russia Ukraine Mexico South Africa South Korea New Zealand India Australia, Ukraine South Africa India EU (No-20) Japan US

Formatted: Line spacing: single

Sulbactomax

Formatted: Line spacing: single

Potentox

Formatted: Line spacing: single

Tobracef Aceclofenac

1 21

Formatted: Line spacing: single Formatted: Line spacing: single

Vancoplus

South Africa New Zealand Ukraine

Formatted: Line spacing: single

Total

75

Formatted: Line spacing: single

VRL has filed more than 700 Dossiers in various countries like North America, South America, Europe, Africa, CIS & Middle east, South East Asia, Australia and New Zealand and of the same Venus has got the registrations in hand of around 326 Dossiers.Explain more here R&D pipeline of products Pan-India marketing presence covering 24 States and two Union Territories, supported by over 700 marketing professionals, over 40 distributors, 2,000 stockists, 40,000 chemists and 120,000 doctors Offices in Africa, Asia-Pacific, CIS, Europe, Latin America and Middle East countries. Marketing footprints across 60 countries (regulated & emerging) with a presence across 25 countries supported by 11 overseas offices. Marketing footprints across 60 countries (regulated & emerging) with an export presence across 25 countries supported by 11 overseas officesPresently the Company has successfully made its presence in the markets of Canada, United States, Mexico, Guatemala, Salvador, Costa Rica, Colombia, Peru, Jamaica, Dominican Republic, Venezuela, Brazil, Formatted: Indent: Left: 0.25", No bullets or numbering

Ind-Swift Ltd exports its products to more than 50 countries with the help of Global Business Unit(GBU) .

Market Presence

Formatted: Bulleted + Level: 1 + Aligned at: 0" + Indent at: 0.25"

Formatted: Font color: Black, English (India) Formatted: Bulleted + Level: 1 + Aligned at: 0" + Indent at: 0.25" Formatted: Font: 8 pt, Not Italic, Font color: Black, English (India)

Formatted Formatted Formatted United Kingdom, Netherlands, Poland, Czech Republic, Switzerland, Portugal, Germany, Slovenia, Macedonia, Albania, Greece, Niger, Togo, Uganda, Botswana, Zimbabwe, South Africa, Mauritius, Ethiopia, Kenya, Russia, Kenya, Russia, Belarus, Ukraine, Moldova, Croatia, Bosnia, Serbia, Turkey, Syria, Iraq, Iran, Jordan, Kuwait, UAE, Saudi Arabia, India, Pakistan, Burma, Yemen, South Korea, The Philippines, Sri Lanka, Thailand, Vietnam, Cambodia, Malaysia, Indonesia. Formatted Formatted Formatted Formatted Formatted Formatted Formatted Formatted Formatted Formatted Global Reach No of Country North America South America Europe Africa ASIA (CIS & Middle East) Asia (South East) Australia & New Zealand 9 4 20 7 8 10 2 Dossier Filed 52 94 102 146 170 140 4 Dossier Registered 22 44 17 87 105 51 Formatted Formatted Formatted Formatted Formatted Formatted Formatted Formatted Formatted Formatted Formatted Formatted your presence in which Formatted Formatted Formatted Formatted Formatted Formatted Formatted Formatted Formatted Formatted Formatted Formatted Formatted Formatted Formatted Formatted Formatted Formatted Formatted Formatted Formatted

... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ...

kindly mention here continents